Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
about
The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsWhen Prostate Cancer Circulates in the BloodstreamCharacterization of DNA Methylation in Circulating Tumor CellsDNA-Repair Defects and Olaparib in Metastatic Prostate CancerClinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and BackChemotherapy options in castration-resistant prostate cancerTranslating genomic profiling to gastrointestinal cancer treatment.Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3A Versatile Microarray Platform for Capturing Rare CellsRecent advances in preoperative management of esophageal adenocarcinomaAn exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal modelCirculating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Prognostic Impact of Modulators of G proteins in Circulating Tumor Cells from Patients with Metastatic Colorectal Cancer.High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressivenessTargeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.Biomarkers for prostate cancer: present challenges and future opportunities.Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.Global preamplification simplifies targeted mRNA quantification.Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancerThe influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Emerging agents for the therapy of advanced prostate cancer.Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay.The use of circulating biomarkers in early clinical trials in patients with cancer.Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.The role of cell-free DNA in predicting colorectal cancer prognosis.Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution.Application of liquid biopsy in precision medicine: opportunities and challenges.A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors.Functional studies on circulating and disseminated tumor cells in carcinoma patientsValidation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.PBX3 is a putative biomarker of aggressive prostate cancer.Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
P2860
Q26750672-0EBCC79A-55D2-4C2C-840F-70D30C7346DFQ26768470-5DAA2E89-7899-46F3-8493-F1804BB68745Q26778427-2A75A16D-9EFD-42FE-B1FA-728BB77517A7Q27853235-82D33788-08B8-4DB8-8104-330C52BAAC90Q28070333-74BEE6AC-E7FD-4E3A-9DE1-F6B1DD437677Q28078477-A11CFC9D-2A87-4BEE-8590-4E6A2550F537Q30239109-171194C4-118F-4D08-9A82-3D08D38877BBQ30277291-051036AC-E222-43A5-9A72-2C602C560447Q30670232-411314FA-AA6E-4BE7-99C5-DB37B5A7244FQ33589301-9C87E946-CFDF-4474-866F-A2DF02152A1BQ33608134-4D5FE5AB-A20C-42DB-A784-2C423525569AQ33827596-F1895883-2391-4067-8F4C-2A24415EAC8EQ34108738-557C4BEA-EED0-48C0-8954-9A979173871BQ35938840-2609D67A-3A02-4A81-BAF4-887659DE34C8Q36288987-CFD4570C-A3D5-4859-9D90-B4267C8D62E5Q36407003-AC613DA3-8BDC-4E07-A57D-2CAF1990ED08Q36621729-42B71209-5BD4-4FB8-849F-30324E03747BQ37045507-A36D3FBE-6C73-445F-A620-E157E707B782Q37060938-10812ED9-6DB5-41D4-A13E-ED24024D9E6CQ37474443-B1A12265-DE5D-47F4-AB0C-3E4F76B0716AQ37688197-EC83D7B7-179C-4A4F-9D1C-EC40429F808FQ37717262-DAA1CD9E-82CB-4F03-8241-F1BEF110DE77Q38311282-94F92A20-2E77-4466-A1D5-F56823BFCE49Q38342823-BD2D3423-84A3-482E-BE8E-01C5F5C134B1Q38487988-6C0A2ABE-7B0C-42C4-9711-98C322FAF161Q38586459-4253AA54-6728-433C-BDFD-6C6C4F2F823BQ38590310-3B924516-7F2D-4985-8A26-88771A46C88EQ38600479-B06343E6-708B-4644-9F19-0D7EC3F39E1AQ38618888-50816933-3D01-4B0C-A270-9A789CA20FB9Q38637642-A9BED9EA-35A3-48E6-940D-B164398E559FQ38639962-57D9BBD4-8573-4CF4-9639-3ED279181E8DQ38651713-EDFFD583-BB5F-4544-8FD0-B6AC70560298Q38664856-FE9C2471-E65B-410B-826A-3B4DC9238710Q38678110-A1BEF769-E1CA-48A7-96EF-3DD21A96541DQ38693785-CF1705CF-D7D8-41B2-925A-64F16B4350E3Q38720700-29B336EA-FEB5-4552-A49E-EDAC98348B19Q38723767-40D62ADF-00FF-423D-9832-C61DE405C2BEQ38745926-E258E816-0048-4C12-B3E8-CA896D1F4544Q38765965-CFD4F23C-448B-4333-98AC-7745C0F1EE28Q38773250-5432FEE1-3099-4501-942F-547397E1914C
P2860
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@ast
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@en
type
label
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@ast
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@en
prefLabel
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@ast
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@en
P2093
P2860
P50
P356
P1476
Circulating tumor cell biomark ...... tion-resistant prostate cancer
@en
P2093
Arturo Molina
Daniel C Danila
David Olmos
Glenn Heller
Howard I Scher
Johann S de Bono
Martin Fleisher
Robert McCormack
Ruth Riisnaes
Shahneen K Sandhu
P2860
P304
P356
10.1200/JCO.2014.55.3487
P407
P577
2015-03-23T00:00:00Z